Surveillance for Bloodborne Infections

Introduction

Since blood is a biological product, it is a natural vehicle for transmission of infectious agents, and until an artificial blood substitute is developed, the risk of transfusion-transmitted infections will probably not be eliminated. Three agencies of the Department of Health and Human Services–the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institutes of Health (NIH)–have collaborated with partners in local and state public health departments, academia, industry, and consumers to develop prevention strategies addressing emerging infectious disease threats to public health, including the safety of the U.S. blood supply. Four critical components of these prevention strategies are as follows: surveillance and response capabilities; integration of laboratory science and epidemiology (i.e., “applied research”) to optimize public health practice; prevention and control activities to enhance communication of public health information; and a strengthening of local, state, and federal infrastructures to support these activities.¹

As highlighted by the Institute of Medicine, in its series of reports about the ongoing threat to health posed by emerging infectious diseases, surveillance is the critical lynchpin for the public health response to both known and unrecognized pathogenic threats.² Surveillance data can be used to monitor and track temporal and demographic trends of disease, alert us to outbreaks or unexpected alterations in disease frequency or affected populations, serve as a basis for subsequent epidemiologic and laboratory investigations to describe the natural history of a disease or identify risk factors for its occurrence, and evaluate intervention strategies.^2,3

This paper will review programs of surveillance in the U.S. to detect established and emerging infectious risks, with an emphasis on those that address blood safety. In addition, recent examples or case studies that illustrate the responsiveness of U.S. surveillance systems to blood safety issues will be presented.

• References

• 1 Centers for Disease Control and Prevention. Addressing Emerging Infectious Disease Threats: A Prevention Strategy for the United States. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service; 1994
• 2 Institute of Medicine. Emerging Infections: Microbial Threats to Health in the United States. Washington, DC: National Academy Press; 1992
• 3 Thacker SB, Berkelman RL. Public health surveillance in the United States. Epidemiol Rev. 1988; 10: 164-190.
• 4 Centers for Disease Control and Prevention. Preventing Emerging Infectious Diseases: A Strategy for the 21st Century. Atlanta, GA: U.S. Department of Health and Human Services, Public Health Service; 1998
• 5 Centers for Disease Control and Prevention. Surveillance for Creutzfeldt-Jakob disease-United States. MMWR 1996; 45: 665-668.
• 6 Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS, Lewis WF, Notari EP, Petersen LR. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995; 333: 1721-1725.
• 7 Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. for the Retrovirus Epidemiology Donor Study. The risk of transfusion-transmitted viral infections. N Engl J Med. 1996; 334: 1685-1690.
• 8 Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, GA: U.S. Department of Health and Human Services; 1998. 10(No.1): 12.
• 9 Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 56. Atlanta, GA: U.S. Department of Health and Human Services; 1995
• 10 Alter MJ, Hadler SC, Margolis HS, Alexander WJ, Hu PY, Judson FN, Mares A, Miller JK, Moyer LA. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990; 263: 1218-1222.
• 11 Petersen LR, Dodd R, Dondero Jr TJ. Methodologic approaches to surveillance of HIV infection among blood donors. Pub Health Rep. 1990; 105: 153-157.
• 12 Doll LS, Petersen LR, White CR, Ward JW. HIV Blood Donor Study Group. Human immunodeficiency virus type 1-infected blood donors: behavioral characteristics and reasons for donation. Transfusion. 1991; 31: 704-709.
• 13 Zuck TF, Thomson RA, Schreiber GB, Gilcher RO, Kleinman SH, Murphy EL, Ownby HE, Williams AE, Busch MP, Smith JW, Nass CC, Hollingsworth CG, Nemo GJ. for the REDS Group. The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. Transfusion. 1995; 35: 944-951.
• 14 Busch M, Chamberland M, Epstein J, Kleinman S, Khabbaz R, Nemo G. Oversight and monitoring of blood safety in the United States. Vox Sang.. In press.
• 15 Soucie JM, Evatt B, Jackson D. and the Hemophilia Surveillance System Project Investigators. Occurrence of hemophilia in the United States. Am J Hematol. 1998; 59: 288-294.
• 16 Centers for Disease Control and Prevention. Hemophilia Surveillance System Report. 1998 1(No.1): 1-14.
• 17 Sloand EM, Pitt E, Klein HG. Safety of the blood supply. JAMA 995; 274: 1368-1373.
• 18 Wagner SJ, Friedman LI, Dodd RY. Transfusion-associated bacterial sepsis. Clin Micro Rev. 1994; 7: 290-302.
• 19 U.S.. General Accounting Office. Blood Supply. Transfusion-Associated Risks. GAO/PEMD-97-2. Washington, DC: Government Printing Office; 1997
• 20 Centers for Disease Control and Prevention. Red blood cell transfusions contaminated with Yersinia enterocolitica-United States, 1991-1996, and initiation of a national study to detect bacteria-associated transfusion reactions. MMWR 1997; 46: 553-555.
• 21 Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance ST. ed. Blood Supply Risks, Perceptions and Prospects for the Future. Bethesda: American Association of Blood Banks; 1994: 1-24.
• 22 Will RG, Ironside JW, Zeidler M, Cousens N, Estibeiro K, Alperovitch A, Poser S, Pocchiari M, Hofman A, Smith PG. A new variant of Creutzfeldt-Jakob disease in the U.K. Lancet 1996; 347: 921-925.
• 23 Holman RC, Khan AS, Belay ED, Schonberger LB. Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases. Emerg Infectious Dis. 1996; 2: 333-337.
• 24 Schonberger LB. New-variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy: the strengthening etiologic link between two emerging diseases. In: Scheld WM, Craig WA, Hughes JM. eds. Emerging Infections. Washington, DC: American Society of Microbiology; 1998: 1-15.
• 25 Gerber MA, Shapiro ED, Krause PJ, Cable RG, Badon SJ, Ryan RW. The risk of acquiring Lyme disease or babesiosis from a blood transfusion. J Infect Dis. 1994; 170: 231-234.
• 26 Herwaldt BL, Kjemtrup AM, Conrad PA, Barnes RC, Wilson M, McCarthy MG, Sayers MH, Eberhard ML. Transfusion-transmitted babesiosis in Washington State: first reported case caused by a WA1-type parasite. J Infect Dis. 1997; 175: 1259-1262.
• 27 Mintz ED, Anderson JF, Cable RG, Hadler JL. Transfusion-transmitted babesiosis: a case report from a new endemic area. Transfusion 1991; 31: 365-368.
• 28 Well GM, Woodward TE, Fiset P, Hornick RB. Rocky Mountain spotted fever caused by blood transfusion. JAMA 1978; 239: 2763-2765.
• 29 American Association of Blood Banks. FDA issues statement on blood donors possibly exposed to tick-borne pathogens. Weekly Report 1997; 3 (28) 1 2.
• 30 Arguin PM, Singleton J, Rotz L, Marston E, Treadwell T, Slater K, Chamberland M, Schwartz A, Tengelsen L, Olson JG, Childs JE. the Transfusion-Associated Tick-borne Illness Task Force. Transfusion. In press.
• 31 Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang. 1994; 67 (Suppl. 04) 19-23.
• 32 Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, Ciavarella N, Emerson SU, Purcell PH. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med. 1994; 120: 1-7.
• 33 Kedda MA, Kew MC, Cohn RJ, Field SP, Schwyzer R, Song E, Fernandes-Costa F. An outbreak of hepatitis A among South African patients with hemophilia: evidence implicating contaminated factor VIII concentrate as the source. Hepatology. 1995; 22: 1363-1367.
• 34 Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-579.
• 35 Fricke W, Augustyniak L, Lawrence D, Brownstein A, Kramer A, Evatt B. Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project. Transfusion 1992; 32: 707-709.